The estimated Net Worth of Beth Hecht is at least $829 millier dollars as of 15 June 2023. Ms. Hecht owns over 15,853 units of Xeris Biopharma Inc stock worth over $53,880 and over the last 9 years she sold XERS stock worth over $0. In addition, she makes $775,568 as Senior Vice President, General Counsel et Corporate Secretary at Xeris Biopharma Inc.
Sign up
Ms. Hecht XERS stock SEC Form 4 insiders trading
Beth has made over 6 trades of the Xeris Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 15,853 units of XERS stock worth $45,340 on 15 June 2023.
The largest trade she's ever made was exercising 36,798 units of Xeris Biopharma Inc stock on 23 June 2022 worth over $105,242. On average, Beth trades about 2,360 units every 53 days since 2015. As of 15 June 2023 she still owns at least 18,839 units of Xeris Biopharma Inc stock.
You can see the complete history of Ms. Hecht stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Beth Hecht biography
Beth P. Hecht J.D. serves as Senior Vice President, General Counsel, Corporate Secretary of the Company. Ms. Hecht has over twenty-five years of experience as a corporate executive in the life sciences industry, most recently serving from 2012 to 2018 as managing director and chief legal and administrative officer of Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. From November 2013 through November 2014, Ms. Hecht also served as corporate secretary and legal and compliance advisor at Durata Therapeutics, a biopharmaceutical company. Prior to that, she was senior vice president, general counsel and corporate secretary at the Sun Products Corporation from March 2009 through September 2012, and prior to that executive vice president and general counsel of MedPointe Healthcare, Inc., a pharmaceutical company. Ms. Hecht has served on the board of directors of Neos Therapeutics, Inc., a pharmaceutical company, since September 2015 where she chairs the nominating and corporate governance committee. Ms. Hecht received a J.D. from Harvard Law School and a B.A. from Amherst College.
What is the salary of Beth Hecht?
As the Senior Vice President, General Counsel et Corporate Secretary of Xeris Biopharma Inc, the total compensation of Beth Hecht at Xeris Biopharma Inc is $775,568. There are 5 executives at Xeris Biopharma Inc getting paid more, with Paul Edick having the highest compensation of $4,307,640.
How old is Beth Hecht?
Beth Hecht is 56, she's been the Senior Vice President, General Counsel et Corporate Secretary of Xeris Biopharma Inc since . There are 15 older and 2 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.
What's Beth Hecht's mailing address?
Beth's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.
Insiders trading at Xeris Biopharma Inc
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... et Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
What does Xeris Biopharma Inc do?
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
What does Xeris Biopharma Inc's logo look like?
Complete history of Ms. Hecht stock trades at Neos Therapeutics Inc, Aytu BioPharma Inc, Iterum Therapeutics Plc et Xeris Biopharma Inc
Xeris Biopharma Inc executives and stock owners
Xeris Biopharma Inc executives and other stock owners filed with the SEC include:
-
Paul Edick,
Chairman of the Board, Chief Executive Officer -
John Shannon,
President, Chief Operating Officer -
Paul R. Edick,
Chairman & CEO -
Barry Deutsch,
Chief Financial Officer -
John P. Shannon,
Pres, COO & Director -
Beth Hecht,
Senior Vice President, General Counsel, Corporate Secretary -
Beth P. Hecht J.D.,
Sr. VP, Gen. Counsel, Corp. Sec. & Director -
John Schmid,
Lead Independent Director -
BJ Bormann,
Independent Director -
Marla Persky,
Independent Director -
Jeffrey Sherman,
Independent Director -
Dawn Halkuff,
Independent Director -
Mark Thierer,
Independent Director -
Kenneth Johnson,
Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs -
Steven Prestrelski,
Co-Founder, Chief Scientific Officer -
Dr. Steven J. Prestrelski MBA, Ph.D.,
Co-Founder & Chief Scientific Officer -
Kevin McCulloch,
Sr. VP of Global Operations & Bus. Devel. -
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs -
Barry M. Deutsch,
Exec. Officer -
Allison Wey,
Sr. VP of Investor Relations & Corp. Communications -
Steven M. Pieper,
Chief Financial Officer -
Dr. Steven J. Prestrelski,
Co-Founder & Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt L.P....,
-
Partners, Ltd.Palmetto Part...,
-
Barbara Jean Anne Bormann K...,
Director -
Jonathan Rigby,
Director -
Kevin Mc Culloch,
See Remarks -
Steven Pieper,
See Remarks -
John Johnson,
Director -
Garheng Kong,
Director -
Ricki Louise Fairley,
Director